Resources for you and your patients
Whether you need prior authorization (PA) how-to's and templates, telemedicine guidance,
or tools for your patients, we've got you covered. Check out the helpful resources below.
For the acute treatment of migraine in adults. Not for preventive treatment.
Whether you need prior authorization (PA) how-to's and templates, telemedicine guidance,
or tools for your patients, we've got you covered. Check out the helpful resources below.
We're here to help simplify the PA process.
Use the templates below to streamline and save time.
A template to help simplify writing a letter of medical necessity.
A template to help simplify writing a letter of appeal.
Here are some helpful guides in case you have questions or get stuck.
A guide to help you write a letter of medical necessity.
A practice guide to help you write a letter of appeal.
A tool to help you prepare your PA requests for appropriate patients by listing potential criteria that your patients may need to meet for the health plan to approve initial or continued use of Nurtec ODT.
Help your patients make the most out of their virtual care visit.
treating migraine via telemedicineGet tips for prescribing Nurtec ODT via telemedicine (including prescribing electronically and setting favorites).
Ensure your patients have all the information and support they need.
migraine questionnaire tear padA questionnaire that can help you and your patients evaluate whether their current migraine management is working for them.
Savings & Support
Contraindications: Hypersensitivity to Nurtec ODT or any of its components.
Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.
Adverse Reactions: The most common adverse reaction was nausea (2% in patients who received Nurtec ODT compared to 0.4% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.
Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P‑gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.
Use in Specific Populations: Pregnant/breast feeding: It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. Hepatic impairment: Avoid use of Nurtec ODT in persons with severe hepatic impairment. Renal impairment: Avoid use in patients with end-stage renal disease.
Nurtec ODT is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use
Nurtec ODT is not indicated for the preventive treatment of migraine.
Please click here for full Prescribing Information.